Conor James Loy

Conor James Loy

Auto-generated profile, based on publicly available information

Conor James Loy

Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14850

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
ACAlexandre Pellan Cheng
Alexandre Pellan Cheng
MCMatthew Pellan Cheng
Matthew Pellan Cheng
CLConor James Loy
Conor James Loy
JLJoan Sesing Lenz
Joan Sesing Lenz
KCKaiwen Chen
Kaiwen Chen
IVIwijn De Vlaminck
Iwijn De Vlaminck
Significance: Hematopoietic cell transplantation is the gold standard treatment for many blood disorders, including blood cancers. Nonetheless, frequent post-transplant complications limit the long-term benefit of HCT. Here, we find that circulating cell-free DNA is a highly versatile analyte for monitoring of the most important complications of HCT: Graft-Versus-Host Disease, infection, graft failure and disease relapse. We show that these different therapeutic complications can be informed from a single cell-free DNA sequencing assay followed by disease-specific bioinformatic analyses. This test requires only low coverage DNA sequencing and is compatible with small volumes of blood. Cell-free DNA may improve the care of allogeneic HCT recipients by enabling earlier detection and better prediction of the complex array of complications that occur after HCT.

6 September 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
CLConor J. Loy
Conor J. Loy
VSVenice Servellita
Venice Servellita
ASAlicia Sotomayor-Gonzalez
Alicia Sotomayor-Gonzalez
ABAndrew Bliss
Andrew Bliss
JLJoan S. Lenz
Joan S. Lenz
MGMaria Pilar Gutierrez
Maria Pilar Gutierrez
Inflammatory syndromes, including those caused by infection, are a major cause of hospital admissions among children and are often misdiagnosed because of a lack of advanced molecular diagnostic tools. In this study, we explored the utility of circulating cell-free RNA (cfRNA) in plasma as an analyte for the differential diagnosis and characterization of pediatric inflammatory syndromes. We profiled cfRNA in 370 plasma samples from pediatric patients with a range of inflammatory conditions, including Kawasaki disease (KD), multisystem inflammatory syndrome in children (MIS-C), viral infections, and bacterial infections. We developed machine learning models based on these cfRNA profiles, which effectively differentiated KD from MIS-C—two conditions presenting with overlapping symptoms—with high performance [test area under the curve = 0.98]. We further extended this methodology into a multiclass machine learning framework that achieved 80% accuracy in distinguishing among KD, MIS-C, viral, and bacterial infections. We further demonstrated that cfRNA profiles can be used to quantify injury to specific tissues and organs, including the liver, heart, endothelium, nervous system, and the upper respiratory tract. Overall, this study identified cfRNA as a versatile analyte for the differential diagnosis and characterization of a wide range of pediatric inflammatory syndromes.

16 May 2024 in medRxiv
Verified
Preprint
Open access
PDF file
CLConor Loy
Conor Loy
GAGlory Agun
Glory Agun
MCMatthew P. Cheng
Matthew P. Cheng
IGIsabel H. Gonzalez-Bocco
Isabel H. Gonzalez-Bocco
JLJoan Lenz
Joan Lenz
IVIwijn De Vlaminck
Iwijn De Vlaminck
Despite long-standing success of hematopoietic stem cell transplantation (HSCT) in the treatment of blood cancers and severe immune disorders, monitoring post-transplant complications remains challenging, in part because of the limited availability of informative molecular tests. Here, we evaluated the utility of cell-free RNA (cfRNA) in plasma as an analyte to monitor HSCT recipients and predict immune-related complications. We used RNA-sequencing to profile cfRNA in 549 plasma samples collected at predetermined time points from allogeneic HSCT recipients at two transplant centers. We found that cfRNA temporal profiles in recipients with a complication-free course follow a relatively uniform trajectory, whereas recipients who experience complications exhibit divergent trajectories. cfRNA patterns also differed greatly from circulating cell counts, providing complementary information on cell expansion and turnover. We also used cfRNA profiles at early time points to train machine learning models for the early prediction of acute GVHD, chronic and late acute GVHD, and the outcome of immunosuppression taper. We discovered shared signatures that achieved good performance across different scenarios in both cohorts. Overall, our findings provide support for the use of plasma cfRNA profiling to monitor immune related complications of HSCT.

11 August 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AGAnne E. Gardella
Anne E. Gardella
DEDaniel Eweis-LaBolle
Daniel Eweis-LaBolle
CLConor J. Loy
Conor J. Loy
EBEmma D. Belcher
Emma D. Belcher
JLJoan S. Lenz
Joan S. Lenz
IVIwijn De Vlaminck
Iwijn De Vlaminck
People living with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) experience heterogeneous and debilitating symptoms that lack sufficient biological explanation, compounded by the absence of accurate, noninvasive diagnostic tools. To address these challenges, we explored circulating cell-free RNA (cfRNA) as a blood-borne bioanalyte to monitor ME/CFS. cfRNA is released into the bloodstream during cellular turnover and reflects dynamic changes in gene expression, cellular signaling, and tissue-specific processes. We profiled cfRNA in plasma by RNA sequencing for 93 ME/CFS cases and 75 healthy sedentary controls, then applied machine learning to develop diagnostic models and advance our understanding of ME/CFS pathobiology. A generalized linear model with least absolute shrinkage selector operator regression trained on condition-specific signatures achieved a test-set AUC of 0.81 and an accuracy of 77%. Immune cfRNA deconvolution revealed differences in platelet-derived cfRNA between cases and controls, as well as elevated levels of plasmacytoid dendritic, monocyte, and T cell–derived cfRNA in ME/CFS. Biological network analysis further implicated immune dysfunction in ME/CFS, with signatures of cytokine signaling and T cell exhaustion. These findings demonstrate the utility of RNA liquid biopsy as a minimally invasive tool for unraveling the complex biology behind chronic illnesses.

11 January 2023 in medRxiv
Verified
Preprint
Open access
PDF file
ACAdrienne Chang
Adrienne Chang
CLConor J. Loy
Conor J. Loy
JLJoan S. Lenz
Joan S. Lenz
ASAmy Steadman
Amy Steadman
AAAlfred Andama
Alfred Andama
IVIwijn De Vlaminck
Iwijn De Vlaminck
Tuberculosis (TB) remains a leading cause of death from an infectious disease worldwide. This is partly due to a lack of tools to effectively screen and triage individuals with potential TB. Whole blood RNA signatures have been extensively studied as potential biomarkers for TB, but they have failed to meet the World Health Organization’s (WHOs) target product profiles (TPPs) for a non-sputum triage or diagnostic test. In this study, we investigated the utility of plasma cell-free RNA (cfRNA) as a host response biomarker for TB. We used RNA profiling by sequencing to analyze plasma samples from 182 individuals with a cough lasting at least two weeks, who were seen at outpatient clinics in Uganda, Vietnam, and the Philippines. Of these individuals, 100 were diagnosed with microbiologically-confirmed TB. Our analysis of the plasma cfRNA transcriptome revealed 541 differentially abundant genes, the top 150 of which were used to train 15 machine learning models. The highest performing model led to a 9-gene signature that had a diagnostic accuracy of 89.1% (95% CI: 83.6-93.4%) and an area under the curve of 0.934 (95% CI: 0.8674-1) for microbiologically-confirmed TB. This 9-gene signature exceeds the optimal WHO TPPs for a TB triage test (sensitivity: 96.2% [95% CI: 80.9-100%], specificity: 89.7% [95% CI: 72.4-100%]) and was robust to differences in sample collection, geographic location, and HIV status. Overall, our results demonstrate the utility of plasma cfRNA for the detection of TB and suggest the potential for a point-of-care, gene expression-based assay to aid in early detection of TB. One Sentence Summary This study is the first to investigate the utility of circulating RNA in plasma as a new class of host response signature for tuberculosis and provides evidence that plasma RNA signatures are highly specific for TB and robust against differences in patient cohorts and sample processing.

22 June 2022 in medRxiv
Verified
Preprint
Open access
PDF file
CLConor J. Loy
Conor J. Loy
ASAlicia Sotomayor-Gonzalez
Alicia Sotomayor-Gonzalez
VSVenice Servellita
Venice Servellita
JNJenny Nguyen
Jenny Nguyen
JLJoan Lenz
Joan Lenz
CCCharles Y. Chiu
Charles Y. Chiu
Withdrawal Statement: The authors have withdrawn their manuscript owing to data from patients who had not been consented being inadvertently used in the preprint. This has been corrected in the version of the study published in Cell Reports Medicine. Therefore, the authors do not wish this work to be cited as reference for the project. If you have any questions, please contact the corresponding author.